Haematology-Oncology · Clinical trials
Mantle Cell Lymphoma Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About mantle cell lymphoma — and why its trials are hard
Mantle cell lymphoma is a rare, typically aggressive B-cell non-Hodgkin lymphoma defined by the t(11;14) translocation driving cyclin D1 overexpression. It is generally incurable with a variable course, and management is stratified by fitness. Younger, fit patients often receive intensive cytarabine-containing chemoimmunotherapy followed by autologous stem-cell transplant and rituximab maintenance, while older patients receive less intensive regimens such as bendamustine-rituximab. Bruton tyrosine kinase (BTK) inhibitors transformed relapsed disease: ibrutinib (first approved 2013, its accelerated MCL indication later withdrawn), acalabrutinib, and zanubrutinib produce high response rates, and the non-covalent BTK inhibitor pirtobrutinib is approved after prior covalent BTK inhibition. For BTK-inhibitor-relapsed disease, the CD19 CAR T-cell therapy brexucabtagene autoleucel achieves deep, durable remissions. Additional options include bortezomib and lenalidomide. Prognosis is guided by the MIPI index, Ki-67 proliferation, TP53 mutation status, and blastoid morphology, with TP53-aberrant disease responding poorly to standard chemotherapy.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Bortezomib (Velcade) | 2006 | R/R mantle cell lymphoma (later first-line combination) | PINNACLE (first-line: LYM-3002) | Objective response rate | ORR ~33% single-agent in relapsed disease; VR-CAP improved PFS first-line |
| Lenalidomide (Revlimid) | 2013 | R/R mantle cell lymphoma after bortezomib | MCL-001 (EMERGE) | Objective response rate | ORR ~28%, CR ~8% |
| Acalabrutinib (Calquence) | 2017 | R/R mantle cell lymphoma after >=1 prior therapy | ACE-LY-004 | Objective/complete response | ORR ~81%, CR ~40% (accelerated approval) |
| Zanubrutinib (Brukinsa) | 2019 | R/R mantle cell lymphoma after >=1 prior therapy | BGB-3111-206 / -AU-003 | Objective response rate | ORR ~84%, high CR rates (accelerated approval) |
| Brexucabtagene autoleucel (Tecartus) | 2020 | R/R mantle cell lymphoma (post-BTK inhibitor) | ZUMA-2 | Objective/complete response | ORR ~91%, CR ~68% |
| Pirtobrutinib (Jaypirca) | 2023 | R/R mantle cell lymphoma after >=2 lines including a BTK inhibitor | BRUIN | Objective response rate | ORR ~50% in covalent-BTK-inhibitor-pretreated patients (accelerated approval) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in mantle cell lymphoma development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Ibrutinib — SHINE / confirmatory requirements | Accelerated MCL indication voluntarily withdrawn in the US in 2023 | Although SHINE (first-line ibrutinib + bendamustine-rituximab) improved PFS, it showed no OS benefit and added toxicity; the relapsed accelerated approval was withdrawn for commercial/benefit-risk reasons |
| Temsirolimus (mTOR inhibitor) — Phase 3 (study 3066) | Approved in Europe but not by the FDA for MCL | Modest response magnitude and toxicity limited its role; largely superseded by BTK inhibitors |
| Venetoclax (combinations) — SYMPATICO / early-phase | Single-agent and some combination activity did not translate into a broad standalone MCL approval | Depth/durability limited as monotherapy; resistance and tumor lysis considerations |
Choosing the right endpoint
Primary endpoints that matter in mantle cell lymphoma trials
- Objective response rate (ORR) — Basis for accelerated approvals of BTK inhibitors and CAR-T in relapsed disease
- Progression-free survival (PFS) — Key first-line endpoint (e.g., LYM-3002, SHINE) reflecting durable control
- Complete response (CR) rate — Deep remissions with brexu-cel (~68%) predict durability
- Minimal residual disease (MRD) — Increasingly used to assess depth of remission and guide maintenance
- Overall survival (OS) — Ultimate benchmark; scrutinized for first-line intensification (SHINE showed no OS gain)
How iNGENū runs mantle cell lymphoma trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Mantle Cell Lymphoma clinical trials — FAQs
How is mantle cell lymphoma diagnosed?
What role do BTK inhibitors play?
What happens if MCL relapses after a BTK inhibitor?
Ready to discuss your mantle cell lymphoma trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal